Antibiotic resistance is a serious and growing threat in contemporary medicine, emerging as one of the pre-eminent public health concerns of the 21st century. Some 125,000 people across Europe and the USA suffer every year due to bacterial infections resistant to antibiotic treatments. Within these regions, drug-resistant bacteria inflict an additional financial burden on healthcare systems through exaggerated medical costs of up to $35 billion.
Join SMi as this Masterclass will cover an outline of the licensing process, what technical data is needed as part of a product licensing prospectus, what Big pharma looks for and the product evaluation and due diligence processes.
Who Should Attend?
Anyone likely to be involved in the preparation of scientific material for an outward license or in evaluating inward licensing opportunities will benefit from this workshop, which will cover all the key scientific drivers and issues that need to be considered.
David Scott, Licensing and Business Development Consultant, PharmaConsulting
For more information and to book online please visit: www.smi-online.co.uk/antibiotic-license7.asp
Alternatively, please contact: Daniel Lee on email@example.com
Standard Rate: £599